📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Wockhardt Q3 FY26: Revenue up 22% to ₹888 Cr, EBITDA Surges 72% to ₹173 Cr
Wockhardt reported a strong financial performance for Q3 FY26, with revenue growing 22% YoY to ₹888 crore. EBITDA saw a significant jump of 72% to ₹173 crore, with margins expanding to 19.5% from 13.8% in the previous year. Profit After Tax (PAT) improved to ₹61 crore compared to ₹20 crore in Q3 FY25. The growth was primarily driven by a 96% surge in Biotech operations and robust performance in Emerging Markets and the India Branded Business.
Key Highlights
Revenue increased 22% YoY to ₹888 crore; EBITDA grew 72% to ₹173 crore.
Biotech segment revenue reached ₹213 crore, with Emerging Market biotech growing over 50%.
India Branded Business grew 28% to ₹146 crore, aided by Diabetic therapy and NCE (EMROK).
Novel antibiotic Zaynich received EMA Accelerated Assessment; Foviscu successfully met Phase 3 endpoints.
Exceptional items of ₹107 crore for 9M FY26 include impacts from US entity liquidation and the New Labour code.
💼 Action for Investors
Investors should focus on the company's transition toward high-margin biotech and novel antibiotics, particularly the upcoming global launches of Zaynich and Insulin analogs. The significant margin expansion and R&D breakthroughs suggest a positive turnaround trajectory.
Wockhardt Q3 Standalone Revenue Up 32% YoY to ₹430 Cr; Reports Profit of ₹28 Cr
Wockhardt Limited reported a strong year-on-year performance for the quarter ended December 31, 2025, with standalone revenue growing 32% to ₹430 crore. The company achieved a standalone net profit of ₹28 crore, marking a significant turnaround from a loss of ₹22 crore in the same quarter last year. For the nine-month period ending December 2025, the company has turned profitable with a net profit of ₹150 crore compared to a loss of ₹52 crore in the previous year. Profitability for the quarter was slightly impacted by a ₹10 crore exceptional charge related to the new Indian Labour Code compliance.
Key Highlights
Standalone revenue from operations increased 32.3% YoY to ₹430 crore from ₹325 crore.
Reported a standalone net profit of ₹28 crore vs a loss of ₹22 crore in the year-ago period.
Nine-month standalone net profit reached ₹150 crore, a sharp recovery from a ₹52 crore loss in the prior year.
Recognized an exceptional charge of ₹10 crore due to the impact of consolidated Labour Codes.
Basic EPS for the nine-month period improved to ₹9.24 compared to a negative ₹3.36 in the previous year.
💼 Action for Investors
The standalone turnaround and consistent revenue growth are positive signals for the company's core Indian operations. Investors should now focus on the consolidated results to assess the performance of international subsidiaries and the overall debt reduction progress.
Wockhardt President of Manufacturing, Quality & R&D Dr. Sanjeev Kumar Sharma Resigns
Dr. Sanjeev Kumar Sharma, the President of Manufacturing, Quality & R&D at Wockhardt Limited, has resigned from his position effective February 2, 2026. As a designated Senior Management Personnel (SMP), his departure impacts three critical pillars of the company's operations. The resignation is attributed to personal reasons, and he will cease to be an SMP of the company. Investors should note that this role is vital for maintaining regulatory standards and product development pipelines.
Key Highlights
Dr. Sanjeev Kumar Sharma resigned as President - Manufacturing, Quality & R&D effective February 2, 2026.
The official reason provided for the resignation is personal reasons.
The role is classified as Senior Management Personnel (SMP) under SEBI Listing Regulations.
The departure covers oversight of three major departments: Manufacturing, Quality, and R&D.
💼 Action for Investors
Investors should monitor the company's announcement regarding a successor to ensure operational continuity in R&D and quality compliance. No immediate portfolio changes are suggested, but management stability is a key factor for the stock.
Wockhardt's Foviscu Antibiotic Meets Phase 3 Primary Endpoint with 93.23% Clinical Cure Rate
Wockhardt has announced that its fifth novel antibiotic, Foviscu (WCK 4282), successfully met its primary endpoint in a pivotal Phase 3 trial for treating complicated urinary tract infections. The drug demonstrated a clinical cure rate of 93.23%, matching the 92.31% achieved by the gold-standard meropenem, while showing a well-tolerated safety profile. This milestone is significant as it addresses high-resistance ESBL pathogens in a market where approximately 65 lakh treatment courses of similar antibiotics are used annually in India. The drug has already received QIDP designation from the US FDA, enhancing its global commercial potential.
Key Highlights
Foviscu achieved a 93.23% clinical cure rate versus 92.31% for the gold-standard meropenem in Phase 3 trials.
This is Wockhardt's 5th proprietary antibiotic to successfully complete a registration-enabling Phase 3 study.
The trial targeted ESBL-producing pathogens, which accounted for 51.4% of the Enterobacterales isolates in the study.
Foviscu addresses a large domestic market where 65 lakh treatment courses of similar antibiotics are used annually.
The product holds US FDA Qualified Infectious Disease Product (QIDP) status, providing regulatory advantages.
💼 Action for Investors
Investors should monitor the upcoming regulatory filing and approval timelines for Foviscu, as it represents a significant addition to Wockhardt's commercial antibiotic portfolio. The successful Phase 3 result de-risks a key part of the company's R&D pipeline.
Wockhardt Files MAA with EMA for Novel Antibiotic WCK 5222; Eligible for Accelerated Assessment
Wockhardt has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic WCK 5222 (Zaynich®) on January 5, 2026. The EMA has granted the drug 'Accelerated Assessment' status, which will shorten the review timeline across 30 European countries including the EU and EEA. This follows a successful global Phase III trial and a previous NDA filing with the US FDA under fast-track review. As the first Indian-developed New Chemical Entity (NCE) to seek pan-European approval, this marks a major commercial milestone for the company's R&D pipeline.
Key Highlights
WCK 5222 filed with EMA for marketing authorization across 30 European countries on January 5, 2026.
Granted 'Accelerated Assessment' by EMA, allowing for an abridged review period due to high unmet medical needs.
The drug is a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g) targeting multi-drug resistant infections.
WCK 5222 is already under fast-track review by the US FDA and has been filed with Indian regulatory authorities.
Wockhardt's portfolio includes 6 antibiotics with US FDA QIDP designation, supporting its 77% international revenue base.
💼 Action for Investors
Investors should monitor the EMA's review progress as the accelerated status could lead to a faster commercial launch in Europe. This development significantly strengthens Wockhardt's position in the global high-end antibiotic market.
EMA Grants Accelerated Assessment to Wockhardt's WCK 5222 Antibiotic
The European Medicines Agency (EMA) has granted Accelerated Assessment to Wockhardt's novel antibiotic WCK 5222 (Zaynich®), which targets multi-drug resistant Gram-negative infections. This designation is reserved for drugs addressing unmet medical needs and will significantly speed up the review process for pan-European marketing authorization. WCK 5222 has already completed global Phase III trials and has pending applications with the USFDA and Indian regulators. This marks the first time an Indian-discovered New Chemical Entity (NCE) is being submitted for such authorization in Europe.
Key Highlights
EMA grants Accelerated Assessment for WCK 5222 (Zidebactam 1g + Cefepime 2g) to treat life-threatening MDR/XDR infections.
WCK 5222 is the first Indian-discovered NCE submitted for pan-European marketing authorization.
Global Phase III clinical trials are complete, with NDA already filed and accepted by the USFDA.
Wockhardt's pipeline includes 6 antibiotics with USFDA QIDP designation, with 77% of revenue coming from international markets.
💼 Action for Investors
Investors should view this as a major de-risking event for Wockhardt's R&D pipeline, potentially leading to faster commercialization in the European market. Monitor USFDA and Indian regulatory approvals as subsequent catalysts for the stock.
Wockhardt's Zaynich NDA Accepted by US FDA - A First for Indian Pharma
Wockhardt Ltd. announced that the US FDA has accepted the New Drug Application (NDA) for its antibiotic Zaynich, marking the first time an Indian pharmaceutical company has achieved this milestone for a New Chemical Entity (NCE). The NDA was filed on September 30, 2025. Zaynich has received Fast Track designation from the FDA, potentially expediting the review process. This acceptance highlights Wockhardt's innovation and could lead to significant revenue opportunities if the drug is approved.
Key Highlights
US FDA accepts Wockhardt’s New Drug Application for Zaynich
First-ever NDA Acceptance for an Indian Pharmaceutical Company
NDA was originally filed on September 30, 2025
Zaynich has been granted Fast Track designation by the US FDA
Wockhardt initiated Zaynich development program in 2011
💼 Action for Investors
Investors should monitor the FDA's review process for Zaynich, as approval could significantly impact Wockhardt's future revenue and market position. Positive news regarding the review process may present a buying opportunity.